Hower Michael R, Karlapati Surya Kumar, Bachu Anil K
Psychiatry and Behavioral Sciences, Baptist Health - University of Arkansas for Medical Sciences, Little Rock, USA.
Psychiatry and Behavioral Sciences, Oregon State Hospital, Salem, USA.
Cureus. 2024 Jan 3;16(1):e51593. doi: 10.7759/cureus.51593. eCollection 2024 Jan.
Antipsychotics are considered a gold standard treatment for schizophrenia. However, there is considerable variation in antipsychotic medication choice. Factors considered involved include symptomatology, prior response, and adverse reactions. This case report presents a 38-year-old male patient with schizophrenia in acute psychosis refractory to several antipsychotics. Hypotheses for the mechanism of action of antipsychotics and psychopharmacology are discussed, and treatment resistance is defined. The patient's psychiatric, medical, and social history and past antipsychotic medications are reviewed. Afterward, the rationale for initiating perphenazine is discussed, and the patient's improvement with this medication is examined. Current literature on perphenazine's efficacy is also reviewed and discussed alongside its limitations.
抗精神病药物被认为是治疗精神分裂症的金标准。然而,抗精神病药物的选择存在很大差异。考虑的因素包括症状学、既往反应和不良反应。本病例报告介绍了一名38岁的男性精神分裂症患者,其处于急性精神病状态,对多种抗精神病药物均无反应。讨论了抗精神病药物的作用机制和精神药理学的假设,并定义了治疗抵抗。回顾了患者的精神、医学和社会病史以及过去使用的抗精神病药物。之后,讨论了开始使用奋乃静的理由,并检查了该药物对患者的疗效。还回顾并讨论了当前关于奋乃静疗效的文献及其局限性。